Concepedia
Statistics
Publications
36
Citations
3.9K
H-Index
27
Active since
1989
Affiliations
Sarah Cannon(Current)
Cornell University
Stanford University
Dana-Farber Cancer Institute
Washington University in St. Louis
Albert S. Yu is an author at Sarah Cannon specializing in pharmacology, medicine, and pi3k inhibitors.
Publications per year
1989–2023
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown, John C. Byrd, Steven Coutré et al. · Blood · 2014 · 584 citations · Full text
Medicine, Oncology, Pharmacology +14
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel, Sarah Meadows, Mariela Sivina et al. · Blood · 2011 · 548 citations · Full text
Life Sciences, Cancer Biology, Oncology +15
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman et al. · Blood · 2014 · 249 citations
Medicine, Oncology, Pharmacology +16
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2015 · 240 citations · Full text
Pharmacy, Immunology, Pharmacotherapy +9
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Ian W. Flinn, Brad S. Kahl, John P. Leonard et al. · Blood · 2014 · 209 citations · Full text
Medicine, Oncology, Pharmacology +11
1–5 of 36